^
    Back
    Association details:
    Biomarker:EGFR T790L
    Cancer:Lung Adenocarcinoma
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JTO Clin Res Rep
    Title:

    EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma

    Published date:
    05/18/2021
    Excerpt:
    Patient 2 had EGFR T790L identified from needle biopsy of lung tissue at disease progression on icotinib treatment. This patient was subsequently treated with osimertinib and achieved stable disease with a progression-free survival of 9 months.
    DOI:
    10.1016/j.jtocrr.2021.100185